Omadacycline pharmacokinetics/pharmacodynamics in the hollow fiber model and clinical validation of efficacy to treat pulmonary Mycobacterium abscessus disease
Journal
International journal of antimicrobial agents
Journal Volume
62
Journal Issue
1
Date Issued
2023-07
Author(s)
Singh, Sanjay
Heysell, Scott K
McShane, Pamela J
Wadle, Carly
Shankar, Prem
Huang, Hung-Ling
Pasipanodya, Jotam
Boorgula, Gunavanthi D
Philley, Julie V
Gumbo, Tawanda
Srivastava, Shashikant
Abstract
Guideline-based therapy (GBT) for pulmonary Mycobacterium abscessus (Mab) disease achieves sustained sputum culture conversion (SSCC) rates of 30%; this is reflected by poor efficacy of GBT in the hollow fiber system model of Mab (HFS-Mab), which killed ∼1.22 log10 CFU/mL. This study was performed to determine which clinical dose of omadacycline, a tetracycline antibiotic, should be used in combination therapy to treat pulmonary Mab disease for relapse-free cure.
Subjects
Efficacy; Hollow fiber system model; M. abscessus; Pharmacokinetics/pharmacodynamics; Safety
Type
journal article